HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Birth Control Not Good For Women's Health, Natural Family Planning Group Says

Executive Summary

SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”

You may also be interested in...



Canada Responds To Children’s OTC Pain Reliever Shortage Linked To Consumers ‘Panic Buying’

Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.

PCPC Raises ‘Grave Concerns’ About China’s Cosmetic Regs, Possible WHO Treaty Noncompliance

Foreign cosmetic product manufacturers may avoid the Chinese market if burdensome registration requirements aren’t modified and fairness issues addressed, the trade association says in comments to the Office of the US Trade Representative.

20 Democrat, 1 GOP State AGs Frame OTC Birth Control Within Protecting Reproductive Rights

Citing national uncertainty regarding reproductive health care – “ a time when reproductive rights have been curtailed across the country – state AGs urge FDA to approve OTC birth control proposal from HRA Pharma.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS153105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel